Pretargeted brain PET imaging reveals amyloid-β pathology using a TCO-modified antibody and a fluorine-18-labeled tetrazine

This study demonstrates successful pretargeted PET imaging of brain Aβ pathology using a systemically administered bispecific antibody capable of BBB penetration and a fluorine-18-labeled tetrazine. These findings establish a generalizable strategy for high-contrast in vivo imaging of brain protein targets using pretargeted PET, with the potential to expand molecular imaging to protein targets in the brain that are currently inaccessible.